Provided by Tiger Trade Technology Pte. Ltd.

Apellis Pharmaceuticals Inc.

22.13
-0.3400-1.51%
Post-market: 22.00-0.1300-0.59%16:15 EST
Volume:3.87M
Turnover:84.96M
Market Cap:2.80B
PE:61.79
High:22.67
Open:21.12
Low:20.10
Close:22.47
52wk High:30.48
52wk Low:16.10
Shares:126.53M
Float Shares:78.12M
Volume Ratio:2.20
T/O Rate:4.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3581
EPS(LYR):-1.5970
ROE:14.10%
ROA:5.13%
PB:6.98
PE(LYR):-13.86

Loading ...

J.P. Morgan Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Nov 05, 2025

Stock Track | Apellis Pharmaceuticals Plummets 5.05% as Mizuho Slashes Price Target

Stock Track
·
Nov 04, 2025

Stock Track | Apellis Pharmaceuticals Plunges 5% as Mizuho Slashes Price Target

Stock Track
·
Nov 04, 2025

Stock Track | Apellis Pharmaceuticals Plunges 5% Pre-Market as Multiple Analysts Cut Price Targets

Stock Track
·
Oct 31, 2025

Wedbush Lowers Price Target on Apellis Pharmaceuticals to $22 From $23, Keeps Neutral Rating

MT Newswires Live
·
Oct 31, 2025

Apellis Pharmaceuticals (APLS) Receives a Hold from RBC Capital

TIPRANKS
·
Oct 31, 2025

Apellis Pharmaceuticals (APLS) Receives a Hold from Morgan Stanley

TIPRANKS
·
Oct 31, 2025

Apellis Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 31, 2025

Apellis price target lowered to $45 from $57 at H.C. Wainwright

TIPRANKS
·
Oct 31, 2025

U.S. RESEARCH ROUNDUP-Amazon, Apple, Cigna

Reuters
·
Oct 31, 2025

Apellis price target lowered to $27 from $29 at BofA

TIPRANKS
·
Oct 31, 2025

Apellis Pharmaceuticals Down Nearly 24%, on Pace for Largest Percent Decrease Since July 2023 -- Data Talk

Dow Jones
·
Oct 30, 2025

Apellis falls -19.3%

TIPRANKS
·
Oct 30, 2025

Stock Track | Apellis Pharmaceuticals Plummets 22.30% Despite Beating Q3 Earnings Estimates

Stock Track
·
Oct 30, 2025

Stock Track | Apellis Pharmaceuticals Plunges 10.15% Pre-market Despite Beating Q3 Estimates

Stock Track
·
Oct 30, 2025

Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q3 EPS $1.67, vs. FactSet Est of $1.60

MT Newswires Live
·
Oct 30, 2025

Apellis Pharmaceuticals Q3 Basic EPS USD 1.71

Reuters
·
Oct 30, 2025

Apellis Q3 revenue jumps to $459 mln with Sobi payment

Reuters
·
Oct 30, 2025

Apellis Pharmaceuticals Inc - Cash and Cash Equivalents of $479 Mln as of Sept 30, 2025

THOMSON REUTERS
·
Oct 30, 2025

Apellis Pharmaceuticals Q3 Operating Income USD 223.183 Million

THOMSON REUTERS
·
Oct 30, 2025